(COMTEX) B: Simulations Plus Expands Discovery Market with the Licens
B: Simulations Plus Expands Discovery Market with the Licensing of its
Predictive Software to Scriptgen Pharmaceuticals Inc.
LANCASTER, Calif., Mar 29, 2000 (BUSINESS WIRE) -- Simulations Plus Inc.
(OTCBB:SIMU)(www.simulations-plus.com), a premier developer of drug discovery
and development simulation software for the pharmaceutical and biotechnology
industries, today announced that it has expanded into the anti-infective market
with the licensing of both its GastroPlus(TM) and QMPRPlus(TM) software programs
to Scriptgen Pharmaceuticals Inc. Scriptgen Pharmaceuticals is a leader in the
discovery of drugs to control the expression of genes. While the user market for
Simulations Plus' novel absorption simulation has grown to seventeen of the
world's leading pharmaceutical corporations, Scriptgen is the first licensee
that is dedicated to the control of gene expression. Simulations Plus is the
leading provider of absorption simulation software and related consulting
services in the world.
Scriptgen Pharmaceuticals Inc. is a leader in the discovery of drugs to control
the expression of genes. Its current programs in the anti-infectives area are
targeted to identify multiple new drug targets and lead compounds effective
against drug-resistant bacterial, fungal, and viral pathogens. Scriptgen's
products include GATE, a family of high-throughput target identification and
validation technologies, and ATLAS and SCAN, high-throughput screening
technologies for proteins and RNA targets, respectively.
Simulations Plus launched GastroPlus(TM) in September 1998, as the first
commercial product in its expanding suite of ADME (absorption, dissolution,
metabolism and excretion) predictive software. The four ADME characteristics
must be determined for all potential new oral drug compounds, beginning in drug
discovery. Simulations Plus software allows the pharmaceutical scientist to
assess these characteristics through computer software rather than through
traditional lab experiments. With an estimated 80 percent of all drugs on the
market being administered orally, these studies must be performed on the
majority of new compounds. The value of Simulations Plus' groundbreaking
software is that it can reduce the need for traditional time-consuming and
expensive laboratory studies, thereby accelerating drug discovery and
development.
"We are very excited about adding Scriptgen Pharmaceuticals to our prestigious
list of GastroPlus and QMPRPlus users worldwide," said Walt Woltosz, chairman
and chief executive officer of Simulations Plus Inc. "With a strong and growing
following among the pharmaceutical giants, we are pleased to be expanding into
one of the most vibrant segments of biotechnology today -- modulation of gene
expression. Our technologies are applicable to the discovery and development of
all oral drugs, allowing for great opportunity as the science of drug discovery
expands."
Simulations Plus Inc. is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by biotechnology and pharmaceutical companies
worldwide. The Company has two other businesses, Words+ Inc. and FutureLab(TM),
which are based on its proprietary software technologies and which provide
support for the emerging pharmaceutical enterprise. Simulations Plus Inc. is
headquartered in Southern California and trades on the OTCBB under the symbol
"SIMU."
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
-- With the exception of historical information, the matters discussed in this
news release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: continuing demand for the
Company's products; competition; continuing customer acceptance of the Company's
products and acceptance of the Company's new products. Further information on
the Company's risk factors is contained in the Company's quarterly and annual
reports as filed with the Securities and Exchange Commission.
Distributed via COMTEX.
Copyright (C) 2000 Business Wire. All rights reserved.
-0-
CONTACT: Simulations Plus Inc.
Ron Creeley, 661/723-7723
or
Banchik & Associates
Doris Banchik, 805/688-2340
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
SOFTWARE
PHARMACEUTICAL
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
*** end of story *** |
